The Lens on LEN primer provides insights on injectable Lenacapvir (LEN) as a promising HIV prevention option, background on the trials, raises questions and explores next steps. This follows the announcement by Gilead sciences in an early review of data from the PURPOSE 1 trial that was conducted among cisgender women in South Africa and Uganda.